Russian Heart Failure Journal 2009year Are new approaches to rescue therapy for decompensated CHF possible? Challenges of evaluating endpoints


To access this material please log in or register

Register Authorize
2009/

Are new approaches to rescue therapy for decompensated CHF possible? Challenges of evaluating endpoints

Arutyunov A.G.

Keywords:

DOI:

Urgency. Circulatory decompensation remains the most life-threatening complication of CHF, which requires rescue therapy. New approaches to the treatment of decompensated heart failure (DHF), which would influence the prognosis of patient, are presently the most urgent. Aim. To develop and test in clinical practice new approaches to the treatment of circulatory decompensation based on control of heart rate and inotropic support. Materials and methods. A one-center, pilot, randomized study on the clinical efficiency of the levosimendan and ivabradin combination in 41 patients with decompensated CHF. Duration of hospitalization, mortality, pulmonary artery wedge pressure (PAWP), coronary artery perfusion pressure (CAPP), blood level of NT-proBNP and clinical condition by CCS were evaluated. Results. We failed influencing the future frequency of hospitalizations using the acute period therapy. Nevertheless we achieved a maximum reduction of the risk for unfavorable outcomes in patients with acute phase of DHF using new approaches to correction and the earliest possible stabilization of hemodynamics.
  1. Фомин И. В., Беленков Ю. Н., Мареев В. Ю. и др. Распространенность ХСН в Европейской части Российской Федерации – данные ЭПОХА-ХСН. Журнал Сердечная Недостаточность. 2006; 7 (1):4–7.
  2. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Данелиян М. О. Первые результаты национального эпидемиологического исследования – ЭПидемиологическое Обследование больныХ ХСН в реальной прАктике (по Обращаемости) – ЭПОХА-О-ХСН. Журнал сердечная недостаточность. 2003; 4 (3):116‑120.
  3. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society on Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008; 10 (10):933‑989.
  4. Cowie MR, Mosterd A, Wood DA et al. The epidemiology of heart failure. Eur Heart J. 1997; 18 (2):208‑225.
  5. Munger MA. Management of acute decompensated heart failure: treatment, controversy, and future directions. Pharmacotherapy. 2006; 26 (8 Pt 2):131S-138S.
  6. Silvers SM, Howell JM, Kosowsky JM. American College of Emergency Physicians Clinical Policies Subcommittee,Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. Ann Emerg Med. 2007; 49 (5):627‑669.
  7. Petersen JW, Felker GM Inotropes in the management of acute heart failure. Crit Care Med. 2008; 36 (1 Suppl):S106-111.
  8. Endoh M, Hori M. Acute heart failure: inotropic agents and their clinical uses. Expert Opin Pharmacother. 2006; 7 (16):2179–2202.
  9. Remme WJ, Torp-Pedersen C, Cleland JG et al. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol. 2007; 49 (9):963‑971.
  10. Cleland JGF, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006; 8 (1):105‑110.
  11. Innes CA, Wagstaff AJ. Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs. 2003; 63 (23):2651–2671.
  12. Savelieva I, Camm AJ. I f inhibition with ivabradine: electrophysiological effects and safety. Drug Saf. 2008; 31 (2):95‑107.
  13. Purcell H, Mach F. Heart rate as a cardiovascular risk factor: potential clinical benefit with ivabradine. Rev Med Suisse. 2007; 3 (113):1375–1378.
  14. Nieminen M, Akkila J, Hasenfuss G et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000; 36 (6):1903–1912.
  15. Pagel PS, Harkin CP, Hettrick DA, Warltier DC. Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs. J Pharmacol Exp Ther. 1995; 275 (1):127‑135.
  16. Effect Heart failure vortality predictor model. Availible at http://www.ccort.ca / Research / CHFRiskModel / tabid / 66 / Default.aspx
  17. Metra M, Torp-Pedersen C, Cleland JG et al; COMET investigators. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail. 2007; 9 (9):901‑909.
  18. Sukonthasarn A. J Prognostic value of heart rate in cardiovascular disease. Med Assoc Thai. 2007; 90 (11):2538–2540.
  19. Ikonomidis I, Parissis JT, Paraskevaidis I et al Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure. Eur J Heart Fail. 2007; 9 (12):1172–1127.
  20. Yilmaz MB, Yalta K, Yontar C et al Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther. 2007; 21 (6):431‑435.
  21. Сычева И. М., Виноградов А. В. Хроническая недостаточность кровообращения. – М.: Медицина, 1977. – 208с.
  22. Prof. Gheorghiade Mihai. Acute heart failure syndromes Road Map for Trials in Acute Heart Failure Syndromes: Towards a Transatlantic Consensus 6th International Meeting 2009 Presidium final report. Availible at http://ahfs.overcome.eu

To access this material please log in or register

Register Authorize
Ru En